:* For treating PARKINSON'S DISEASE, an initial oral dose (tablet or elixir) of 1 milligram the first day followed by increases of 2 milligram increments at 3 to 5 day intervals to a total dose of 6 to 10 milligrams/day in 3 to 4 divided doses is recommended. Postencephalitic patients may require 12 to 15 milligrams/day.
:* It is recommended that trihexyphenidyl be taken in 3 divided doses at mealtime. If the total daily dose is greater than 10 milligrams/day it may be given in 4 divided doses (at mealtime and bedtime).
:* The recommended dose of trihexyphenidyl when used concomitantly with levodopa is 1 to 2 milligrams three times daily.
:* Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.
=====Condition2=====
=====Parkinsonism due to drug=====
* Dosing Information
* Dosing Information
:* Dosage
:* For treating DRUG-INDUCED PARKINSONISM, five to 15 milligrams as a total daily dose is recommended to control extrapyramidal effects from phenothiazines, thioxanthenes and butyrophenones. It is recommended that therapy be initiated with a single 1-milligram dose. If the extrapyramidal manifestations are not controlled in a few hours, subsequent doses may be progressively increased until satisfactory control is achieved.
:* Satisfactory control may sometimes be more rapidly achieved by a temporary dose reduction of the tranquilizer when instituting trihexyphenidyl therapy and adjusting the dose of both drugs until the desired effect is obtained.
=====Condition3=====
:* Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.
* Dosing Information
:* Dosage
=====Condition4=====
* Dosing Information
:* Dosage
<!--Off-Label Use and Dosage (Adult)-->
<!--Off-Label Use and Dosage (Adult)-->
Line 251:
Line 241:
<!--Use in Specific Populations-->
<!--Use in Specific Populations-->
|FDAPregCat=
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 318:
Line 307:
<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=*
|storage=
|packLabel=<!--Patient Counseling Information-->
|packLabel=
<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
Line 327:
Line 314:
<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
Content
Overview
Trihexyphenidyl is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include nausea, xerostomia, dizziness, blurred vision, feeling nervous.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Parkinson's disease
Dosing Information
For treating PARKINSON'S DISEASE, an initial oral dose (tablet or elixir) of 1 milligram the first day followed by increases of 2 milligram increments at 3 to 5 day intervals to a total dose of 6 to 10 milligrams/day in 3 to 4 divided doses is recommended. Postencephalitic patients may require 12 to 15 milligrams/day.
It is recommended that trihexyphenidyl be taken in 3 divided doses at mealtime. If the total daily dose is greater than 10 milligrams/day it may be given in 4 divided doses (at mealtime and bedtime).
The recommended dose of trihexyphenidyl when used concomitantly with levodopa is 1 to 2 milligrams three times daily.
Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.
Parkinsonism due to drug
Dosing Information
For treating DRUG-INDUCED PARKINSONISM, five to 15 milligrams as a total daily dose is recommended to control extrapyramidal effects from phenothiazines, thioxanthenes and butyrophenones. It is recommended that therapy be initiated with a single 1-milligram dose. If the extrapyramidal manifestations are not controlled in a few hours, subsequent doses may be progressively increased until satisfactory control is achieved.
Satisfactory control may sometimes be more rapidly achieved by a temporary dose reduction of the tranquilizer when instituting trihexyphenidyl therapy and adjusting the dose of both drugs until the desired effect is obtained.
Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Trihexyphenidyl in adult patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Trihexyphenidyl in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Trihexyphenidyl in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Trihexyphenidyl in pediatric patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Trihexyphenidyl in pediatric patients.
Contraindications
Condition1
Warnings
ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
Content
Description
Precautions
Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Trihexyphenidyl in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Trihexyphenidyl in the drug label.